Acute myeloid leukemia (aml) Trials in Paris, France
Conditions / Acute myeloid leukemia (aml) / Paris, France
Acute myeloid leukemia (aml) is a medical condition with active clinical research programs worldwide.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04266795 | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy | COMPLETED | PHASE2 |
| NCT04161885 | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | TERMINATED | PHASE3 |
| NCT04603001 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | TERMINATED | PHASE1/PHASE2 |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML | COMPLETED | PHASE2 |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | COMPLETED | PHASE1 |
| NCT01147939 | Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | COMPLETED | PHASE3 |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | COMPLETED | PHASE3 |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | COMPLETED | PHASE1/PHASE2 |